95 related articles for article (PubMed ID: 6249321)
1. Inhibitor of angiotensin I converting enzyme: (4R)-3-[(2S)-3-mercapto-2-methylpropanoyl]-4-thiazolidinecarboxylic acid (YS-980).
Funae Y; Komori T; Sasaki D; Yamamoto K
Biochem Pharmacol; 1980 Jun; 29(11):1543-7. PubMed ID: 6249321
[No Abstract] [Full Text] [Related]
2. Potentiating mechanism of bradykinin action on smooth muscle by sulfhydryl compounds.
Iso T; Nishimura K; Oya M; Iwao J
Eur J Pharmacol; 1979 Mar; 54(3):303-5. PubMed ID: 428428
[TBL] [Abstract][Full Text] [Related]
3. Effects of YS-980, an orally active converting enzyme inhibitor, on blood pressure in normotensive and hypertensive rats.
Komori T; Yamamoto K
Jpn J Pharmacol; 1981 Jun; 31(3):401-7. PubMed ID: 6273629
[TBL] [Abstract][Full Text] [Related]
4. [Inhibition of angiotensin converting enzyme by (2R,4R)-2-(2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4- thiazolidinecarboxylic acid, SA 446].
Horiuchi M; Terashima T; Fujimura K; Shimokawa K; Iso T
Yakugaku Zasshi; 1984 Dec; 104(12):1257-62. PubMed ID: 6099853
[No Abstract] [Full Text] [Related]
5. Antihypertensive effects of the novel converting-enzyme inhibitor YS 980 in spontaneously hypertensive rats.
Unger T; Rockhold RW; Bönner G; Rascher W; Schaz K; Speck G; Schömig A; Ganten D
Clin Exp Hypertens (1978); 1981; 3(1):121-40. PubMed ID: 6258887
[No Abstract] [Full Text] [Related]
6. A new potent inhibitor of converting enzyme: (2R,4R)-2-(2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarboxylic acid(SA446).
Iso T; Yamauchi H; Suda H; Nakata K; Nishimura K; Iwao J
Jpn J Pharmacol; 1981 Dec; 31(6):875-82. PubMed ID: 6174764
[TBL] [Abstract][Full Text] [Related]
7. A novel orally active converting-enzyme inhibitor YS 980: effects on blood pressure in spontaneously hypertensive rats.
Unger T; Rockhold RW; Schaz K; Vescel P; Bönner G; Rascher W; Ganten D
Clin Sci (Lond); 1979 Dec; 57 Suppl 5():157s-160s. PubMed ID: 232020
[TBL] [Abstract][Full Text] [Related]
8. Potentiative effects of sulfhydryl compounds on carrageenin-induced oedema in rats and relationship to their potencies as inhibitors of angiostin-coverting enzyme in vivo.
Iso T; Yamauchi H; Suda H; Nakajima N; Nishimura K; Iwao J
Experientia; 1978 Sep; 34(9):1202-3. PubMed ID: 214334
[TBL] [Abstract][Full Text] [Related]
9. Effects of an orally active converting enzyme inhibitor (YS-980) on renal function in dogs.
Abe Y; Miura K; Imanishi M; Yukimura T; Komori T; Okahara T; Yamamoto K
J Pharmacol Exp Ther; 1980 Jul; 214(1):166-70. PubMed ID: 6156237
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the activity of the angiotensin converting enzyme inhibitors SQ 14 225, SA 446, and MK 421.
Takata Y; Di Nicolantonio R; Mendelsohn FA; Hutchinson JS; Doyle AE
Clin Exp Pharmacol Physiol; 1983; 10(2):131-45. PubMed ID: 6307563
[No Abstract] [Full Text] [Related]
11. Effects of converting enzyme inhibitors on renin-angiotensin system in normal rats.
Komori T; Takada T; Funae Y; Yamamoto K
Osaka City Med J; 1984 Jun; 30(1):17-30. PubMed ID: 6096787
[No Abstract] [Full Text] [Related]
12. [Potentiative effects of angiotensin converting enzyme inhibitors on carrageenan-induced edema in rats].
Suda H; Yamauchi H; Iso T
Nihon Yakurigaku Zasshi; 1982 Dec; 80(6):517-23. PubMed ID: 6298082
[TBL] [Abstract][Full Text] [Related]
13. Effects of angiotensin-converting enzyme inhibitors on the vascular response to norepinephrine.
Saruta T; Suzuki H; Okuno T; Kondo K
Am J Cardiol; 1982 Apr; 49(6):1535-6. PubMed ID: 6176110
[TBL] [Abstract][Full Text] [Related]
14. [Effects of 3 different angiotensin converting enzyme inhibitors, MK 421, SQ 14225 and SA 446 on renal function and blood pressure in patients with essential hypertension].
Tajima J; Abe K; Yasujima M; Tanno M; Yoshinaga K
Nihon Jinzo Gakkai Shi; 1984 Jun; 26(6):779-89. PubMed ID: 6096607
[No Abstract] [Full Text] [Related]
15. Effects of sodium loading on antihypertensive responses to an angiotensin-converting enzyme inhibitor in spontaneously hypertensive and renal hypertensive rats.
Nakata K; Takada T; Yamauchi H; Iso T
Eur J Pharmacol; 1986 Feb; 121(2):293-5. PubMed ID: 3009208
[TBL] [Abstract][Full Text] [Related]
16. Effects of angiotensin I-converting enzyme inhibitor (SA-446) on renal function in dogs.
Takada T; Yamamoto K; Fujioka S; Tamaki T; Fukui K; Abe Y
Jpn J Pharmacol; 1985 Jun; 38(2):227-30. PubMed ID: 2993720
[TBL] [Abstract][Full Text] [Related]
17. Species difference of (2R,4R)-2-(o-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinec arb oxylic acid (SA446) in inhibition of angiotensin converting enzyme.
Nakata K; Iwatani T; Horiuchi M; Kito H; Yamauchi H; Iso T
Jpn J Pharmacol; 1986 Mar; 40(3):367-72. PubMed ID: 3012163
[TBL] [Abstract][Full Text] [Related]
18. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall.
Okunishi H; Miyazaki M; Toda N
J Hypertens; 1984 Jun; 2(3):277-84. PubMed ID: 6099388
[TBL] [Abstract][Full Text] [Related]
19. General pharmacological properties of the potent angiotensin converting enzyme inhibitor rentiapril.
Yamauchi H; Nishimura K; Nakata K; Suda H; Iso T; Shimizu M; Hiramatsu Y
Arzneimittelforschung; 1987 Feb; 37(2):157-64. PubMed ID: 3034298
[TBL] [Abstract][Full Text] [Related]
20. Effect of angiotensin-converting enzyme inhibitor YS980 on prostaglandin synthesis in rabbit kidney medulla slices.
Fujimoto Y; Wada K; Kaneko M; Fujita T
Br J Pharmacol; 1987 Nov; 92(3):479-81. PubMed ID: 3480765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
